These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 4951928)

  • 21. [Use of fraction C-1 in children with hemophilia A].
    Kamińska D; Adamowicz-Salach A; Pytel Z
    Pediatr Pol; 1985 Jan; 60(1):65-8. PubMed ID: 3929224
    [No Abstract]   [Full Text] [Related]  

  • 22. Prophylaxis in haemophilic children.
    Liesner RJ
    Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S7-10. PubMed ID: 9351529
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Prevention of handicapping hemorrhagic complications in severe and moderate hemophilia].
    Landbeck G; Kurme A
    Med Welt; 1973 May; 24(19):763-8. PubMed ID: 4720575
    [No Abstract]   [Full Text] [Related]  

  • 24. Experimental prophylaxis of severe hemophilia with a factor VIII concentrate.
    Shanbrom E; Thelin GM
    JAMA; 1969 Jun; 208(10):1853-6. PubMed ID: 5818829
    [No Abstract]   [Full Text] [Related]  

  • 25. Purification and clinical evaluation of a factor 8 concentrate.
    Johnson AJ; Karpatkin MH; Newman J
    Bibl Haematol; 1970; 34():30-9. PubMed ID: 5436351
    [No Abstract]   [Full Text] [Related]  

  • 26. Experience with prophylaxis in Sweden.
    Nilsson IM
    Semin Hematol; 1993 Jul; 30(3 Suppl 2):16-9. PubMed ID: 8367738
    [No Abstract]   [Full Text] [Related]  

  • 27. [Biological control of substitution therapy in hemophilia A].
    Lisichkov T
    Vutr Boles; 1972; 11(5):103-7. PubMed ID: 4680013
    [No Abstract]   [Full Text] [Related]  

  • 28. Clinical course of factor VIII inhibitors developed after exposure to a pasteurised Dutch concentrate compared to classic inhibitors in hemophilia A.
    Mauser-Bunschoten EP; Rosendaal FR; Nieuwenhuis HK; Roosendaal G; Briët E; van den Berg HM
    Thromb Haemost; 1994 Jun; 71(6):703-6. PubMed ID: 7974335
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Treatment of patients suffering from hemophilia with stenosing hemorrhages into the region of the upper respiratory tract].
    Barkagan ZS
    Vestn Otorinolaringol; 1971; 33(5):93-6. PubMed ID: 5152574
    [No Abstract]   [Full Text] [Related]  

  • 30. Does peroral administration of factor VIII induce oral tolerance in patients with acquired haemophilia A?
    Lindgren A; Wadenvik H; Tarkowski A; Tengborn L
    Thromb Haemost; 2000 Apr; 83(4):632-3. PubMed ID: 10780332
    [No Abstract]   [Full Text] [Related]  

  • 31. [Hemophilia A with factor VIII inhibitor].
    Shima M
    Rinsho Ketsueki; 2003 Feb; 44(2):90-101. PubMed ID: 12692981
    [No Abstract]   [Full Text] [Related]  

  • 32. [Perioperative management of orthopaedic patients with hemophilia A].
    Wu YG; Li XG; Zhang KN; Ren YJ; Li SF; Lu MY
    Zhonghua Wai Ke Za Zhi; 2004 Dec; 42(23):1430-3. PubMed ID: 15733456
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bedside measurement of factor VIII:C activity in individuals with hemophilia A.
    Kessler CM; Bernstein Z; Ghesani S; Shamsipour Z; Frances C; Zucker ML; LaDuca FM
    Am J Hematol; 1996 Mar; 51(3):181-5. PubMed ID: 8619397
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The treatment of hemophilia A with a new antihemophilic fraction "AHF SRK (human)". Comparison with the antihemophilic globulin AHG SRK].
    Duckert F; Müller G; Meili EO
    Schweiz Med Wochenschr; 1971 Dec; 101(50):1831-8. PubMed ID: 5173501
    [No Abstract]   [Full Text] [Related]  

  • 35. Suppression of inhibitors in haemophilia with corticoids and factor VIII.
    Aznar JA; Jorquera JI; Peiro A
    Thromb Haemost; 1983 Jun; 49(3):248. PubMed ID: 6410535
    [No Abstract]   [Full Text] [Related]  

  • 36. Letter: Factor-VIII concentrate in haemophilia.
    Tamagnini GP; Dormandy KM; Ellis D; Maycock W
    Lancet; 1975 Jul; 2(7926):188. PubMed ID: 49787
    [No Abstract]   [Full Text] [Related]  

  • 37. [Successful induction of immune tolerance and novel hemostatic effects in a hemophilia A with high-responder inhibitor by regular infusions of factor VIII].
    Shima M; Sawamoto Y; Kamisue M; Shibata Y; Tuzi S; Kuwabara M; Tanaka I; Tanizawa T; Tanaka A; Ueda M; Kakishita E; Yoshioka A
    Rinsho Ketsueki; 1996 Nov; 37(11):1303-8. PubMed ID: 8960666
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Importance of corticoids in inhibitor suppression in hemophilia A, in addition to continuing treatment with factor VIII concentrate].
    Aznar JA; Jorquera JI; Marty ML
    Sangre (Barc); 1983; 28(3):265-79. PubMed ID: 6414098
    [No Abstract]   [Full Text] [Related]  

  • 39. [Recombinant activated Factor VII (Novoseven Novo Nordisk) for hemostasis in acquired Factor VIII-inhibitor hemophilia].
    Meili EO; Dazzi H; von Felten A
    Schweiz Med Wochenschr; 1995 Mar; 125(9):405-11. PubMed ID: 7892567
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Family issues in continuous infusion therapy with factor VIII.
    Manco-Johnson MJ
    Blood Coagul Fibrinolysis; 1996 Mar; 7 Suppl 1():S21-5. PubMed ID: 8735793
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.